Reported daily use
Community convention, not a measured pharmacologic interval.
Protocol / Research Dosing Guide
Cardiogen Dosage Guide: Community Schedule, Reconstitution and Safety
An evidence-organized Cardiogen reference separating AEDR laboratory research from unvalidated community protocols and supplier claims.
Last reviewed September 15, 202617 minute readResearch information only
Level 2 — Preclinical evidenceNo verified human trialsNot FDA approved
Cardiogen Quick Start
Cardiogen is the short peptide Ala-Glu-Asp-Arg, commonly abbreviated AEDR. Published work is limited to laboratory, tissue-culture, modeling, and animal contexts concentrated within a small research network; no controlled human trial was identified.
Why researchers care
Cardiac tissue and gene-expression research
Class
Synthetic AEDR tetrapeptide bioregulator
Route reported
Subcutaneous use is community reported
Cycle length
10–20 days reported; not validated
Regulatory status
Not FDA approved
Loading supplier information
Cardiogen Dosing Protocol and Schedule
The supplied source reports subcutaneous amounts from 0.2 to 2 mg daily over short 10-to-20-day courses. These are community conventions, not AEDR human dose-finding results.
| Phase or study | Amount | Frequency / evidence |
|---|---|---|
| Community low | 0.2 mg daily | 10–20 days; unvalidated |
| Community common | 1 mg daily | 10–20 days; unvalidated |
| Community high | 2 mg daily | 10–20 days; unvalidated |
No human study establishes an amount, route, schedule, cycle, repeat interval, or rest period for Cardiogen.
Cardiogen Supplies Needed
Neutral research-material planning only. This does not establish an appropriate amount or route.
Research planning item
Exact labeled research vial
Research planning item
Measured diluent volume
Research planning item
U-100 measurement reference
Research planning item
Alcohol swabs
Research planning item
Appropriate sharps container
Research planning item
Written concentration label
Cardiogen Reconstitution Calculator
Vial-format concentration math
Concentration
10 mg/mL
Draw volume
0.1 mL
U-100 units
10
Mathematical draws
20
Arithmetic only. The entered amount is not a recommendation and does not establish suitability.
Best Time to Take Cardiogen: Morning or Night?
Morning or evening?
Morning use appears in community descriptions only; no preferred time is established.
Once daily?
Once-daily use is community reported and not trial validated.
With food?
Not applicable to the reported vial route and not established.
Missed amount?
No validated replacement or doubling instructions exist.
Cardiogen Route Comparison
| Route | Research context | Evidence limit |
|---|---|---|
| Cell and tissue culture | Published mechanistic experiments | No human exposure |
| Subcutaneous | Community reported | No clinical route study |
| Oral | Commercial bioregulator context | No verified AEDR bioavailability study |
| Route conversion | Not established | Formats are not interchangeable |
Routes and amounts are not interchangeable unless a verified study explicitly establishes a conversion.
Cardiogen Half-Life and Dosing Frequency
| Measure | Finding | Evidence limit |
|---|---|---|
| Human half-life | Not established | No human PK study |
| Animal half-life | Not established | No in-vivo PK source located |
| Bioavailability | Not established | Transport models are not exposure measurements |
| Frequency | Daily is community reported | Not experimentally validated |
Cardiogen Dosage Chart
| Route | Amount | Frequency | Source | Human validation |
|---|---|---|---|---|
| Subcutaneous | 0.2 mg | Once daily | Community report | No |
| Subcutaneous | 1 mg | Once daily | Community report | No |
| Subcutaneous | 2 mg | Once daily | Community report | No |
Published study values describe those studies. Community-reported values are not validated dosing recommendations.
Cardiogen Reconstitution Guide
Concentration: 10 mg/mL
| Entered amount | Volume | U-100 units |
|---|---|---|
| 1 mg | 0.1 mL | 10 units |
| 2 mg | 0.2 mL | 20 units |
| 3 mg | 0.3 mL | 30 units |
- 1.Confirm the exact vial label and total quantity.
- 2.Record the measured diluent volume.
- 3.Clean the vial stopper.
- 4.Add liquid slowly along the vial wall.
- 5.Swirl gently; do not shake.
- 6.Inspect for cloudiness, discoloration, or particles.
- 7.Label the calculated concentration and preparation date.
- 8.Use the result only for arithmetic, not as a recommendation.
Reconstitution does not establish identity, purity, sterility, stability, or an appropriate amount.
How Cardiogen Works
AEDR sequence
Cardiogen is described as the tetrapeptide Ala-Glu-Asp-Arg.
Cardiogen Human Trials and FDA Status
Current status · verified September 15, 2026
Not FDA approved
- No registered or published controlled human Cardiogen trial was identified.
- An older Russian study examined myocardial tissue culture and animal contexts, not a human treatment regimen.
- Recent reviews discuss AEDR gene-expression and transport hypotheses.
- Most direct literature comes from the same research group and lacks independent replication.
- A registry study using the acronym CARDIOGEN concerns genistein and is unrelated to this peptide.
Who Should Avoid Cardiogen?
This is an evidence-gap and precaution list, not an approved prescribing label.
Pregnancy or breastfeeding
No safety data
Children or adolescents
No safety data
Cardiovascular disease
No clinical safety or efficacy evidence
Known ingredient sensitivity
Potential allergic risk
Concurrent medicines
No interaction studies
Long-term or repeated use
No safety data
Cardiogen Side Effects, Risks and Safety
Injection-site irritationAnecdotal
Important limitation: No controlled incidence data.
Systemic adverse effectsUnknown
Important limitation: No human safety dataset.
Cardiovascular effectsUnknown
Important limitation: No clinical hemodynamic assessment.
Immune reactionUnknown
Important limitation: No characterized immunogenicity data.
Drug interactionsUnknown
Important limitation: No interaction studies.
Long-term effectsUnknown
Important limitation: No follow-up evidence.
Cardiogen Timeline and Monitoring
10–20 days
Community course length, not a clinical study period.
Repeat cycle
Not established; no restart criteria exist.
Monitoring
No validated biomarker panel, stopping rule, or follow-up schedule exists.
Cardiogen Benefits and Results: What the Evidence Shows
| Claim | Evidence level | What research shows | Important limitation |
|---|---|---|---|
| Cardiac tissue support | Not established in humans | Tissue-culture and animal context | No controlled human trial |
| Gene-expression effects | Preclinical | Small-group laboratory literature | Clinical meaning unknown |
| Cardiovascular aging | Not established | Mechanistic hypothesis | No efficacy endpoint |
| Exercise or recovery | Not established | Community claim | No direct evidence |
Cardiogen Storage and Handling
Unreconstituted vial
No Cardiogen-specific stability study was identified.
Prepared vial
Community refrigeration and 28-day guidance are not validated stability evidence.
Commercial oral products
Formulations may differ and are not interchangeable with pure AEDR.
Appearance
Visual inspection cannot establish identity, purity, or sterility.
Cardiogen Troubleshooting
The solution looks abnormal
Stop and seek qualified product guidance; appearance cannot confirm sterility.
The units do not match another chart
Recheck total vial mg, liquid mL, entered amount, and U-100 conversion.
A CARDIOGEN trial appears in search
Confirm the intervention: the registered genistein study is unrelated to AEDR.
A mechanism is presented as clinical proof
Return to the study model; cell findings do not establish human benefit.
A scheduled amount is missed
No validated missed-amount procedure exists.
Cardiogen Comparisons
| Compound | Class or mechanism | Evidence | FDA status |
|---|---|---|---|
| Cardiogen | AEDR tetrapeptide | Laboratory/preclinical evidence | Not approved |
| Cartalax | AED tripeptide | Laboratory/preclinical evidence | Not approved |
| Vesugen | Short peptide bioregulator | Limited preclinical evidence | Not approved |
Cardiogen Frequently Asked Questions
What is Cardiogen?
The synthetic tetrapeptide Ala-Glu-Asp-Arg, also called AEDR.
Is it FDA approved?
No.
Are there human trials?
No controlled human Cardiogen trial was identified.
What is its half-life?
Not established.
Is subcutaneous use validated?
No; it is community reported.
Is a 10-to-20-day course validated?
No.
Does CARDIOGEN on ClinicalTrials.gov refer to this peptide?
No; that acronym identifies an unrelated genistein study.
Are cardiac benefits established in people?
No.
Is long-term safety known?
No.
What does the calculator do?
It performs concentration and volume arithmetic only.
Sources and Research
Coverage source
1. Cardiogen community dosing guide
Coverage source for community schedule; not primary clinical evidence.
Open direct sourcePreclinical review
2. Peptide regulation of gene expression: a systematic review
Review of short-peptide laboratory research, including AEDR context.
Open direct sourcePreclinical research
3. Cardiogen in myocardial tissue culture
Older preclinical myocardial tissue-culture research.
Open direct sourceMissing information flagged for review
- Controlled human evidence: Not established
- Human dose and route: Not established
- Human and animal pharmacokinetics: Not established
- Validated cycle and rest period: Not established
- Compound-specific stability: Not established
- Human safety and interactions: Not established
- Independent replication: Not established